Hikma launches generic Advair Diskus® following FDA approval
https://www.hikma.com/news/hikma-launches-generic-advair-diskus-following-fda-approval/
WebLondon, 17 December 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline’s Advair Diskus® [1] (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.
DA: 52 PA: 9 MOZ Rank: 60